Navigation Links
Study of DuraPrep versus chlorhexidine
Date:10/9/2009

3M Health Care today announced the publication of a new independent study "Effects of Preoperative Skin Preparation on Postoperative Wound Infection Rates: A Prospective Study of 3 Skin Preparation Protocols," that compared the effects of three different skin preparation solutions on surgical-site infections. The study found that Iodophor-based skin preparation solutions, such as 3M DuraPrep Surgical Solution (Iodine Povacrylex [0.7% available Iodine] and Isopropyl Alcohol, 74% w/w) Patient Preoperative Skin Prep, may be superior to chlorhexidine in preventing surgical-site infections.

Authored by Brian R. Swenson, MD, Robert G. Sawyer, MD, and colleagues from the University of Virginia Health System in Charlottesville, VA, the study appears in the October 2009 issue of the journal Infection Control and Hospital Epidemiology.

The study, which examined more than 3,200 general surgery patients during an 18-month period, was performed in concert with ongoing data collection for the American College of Surgeons' National Surgical Quality Improvement Project (NSQIP). This program, which employs a prospective, peer-controlled, validated database to quantify 30-day risk-adjusted surgical outcomes, is a tool to measure and report surgical quality and outcomes and is recognized by the Institutes of Medicine, the Joint Commission and the American Board of Surgery.

"The main findings of the study were somewhat unexpected. Based on data derived from central venous catheter insertions, we had thought that the infection rates would be lowest in the period where chlorhexidine was the preferred agent for skin preparation. This was not the case. If these findings are reproduced in a multicenter study, switching to iodine-based preparations on a broad basis could significantly reduce the huge morbidity and cost associated with surgical site infection in this country and abroad," said Robert G. Sawyer, M.D., Professor of Surgery and Public Health Science, Co-director Surgical Trauma Intensive Care Unit and Director of Surgical Nutrition Services at the University of Virginia Health System and co-author on the study.

"To date, there have only been limited studies comparing the impact of various skin preparation solutions on surgical-site infections. Previous studies examined only specific surgical sites or relied on less impactful surrogate endpoints such as microbial counts. Dr. Sawyer's study provided a broader assessment of general surgery patients and specifically examined means to reduce the risk of surgical-site infections," said Debra Rectenwald, Vice President and General Manager 3M Infection Prevention Division, 3M Health Care. "We are pleased that DuraPrep solution has been proven effective in the fight against surgical-site infections, and that hospitals, like the University of Virginia Health System, are updating their protocols to include its use."


'/>"/>

Contact: Molly Rabinovitz
mrabinovitz@wcpglobal.com
312-646-6294
WeissComm Partners
Source:Eurekalert

Related medicine news :

1. Researchers report benefits of new standard treatment study for rare pediatric brain cancer
2. Feinstein Investigators Receive Federal GO Grant to Study the Genetics of Schizophrenia
3. Miscarriage Treatment Wont Harm Future Fertility: Study
4. Shingles Raises Stroke Risk: Study
5. Major health care challenges persist for D.C. children despite high rates of health insurance coverage, RAND study finds
6. Radiation costs vary widely by delivery, U-M study finds
7. A study to prevent sudden death in sports by means of genetic testing
8. International Study Finds New Best Practices to Reduce Fire Casualties
9. Long-Term Back Pain Not Inevitable, Study Finds
10. Birth Control Pills Might Alter Mate Selection: Study
11. Rare head and neck cancer linked to HPV, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 top five ... art competition. Selected from 15 submissions from around the nation, the top five finalists ... iaedp Symposium, March 22 – 26 in Las Vegas. , This year, the competition ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... specializes in thought leadership , media relations, social media, content marketing and ... will be powered through Act-On, an intuitive marketing automation platform. , Rosica will ...
(Date:2/23/2017)... Austin, TX (PRWEB) , ... February 23, 2017 ... ... has announced an official 2017 partnership with The Jensie Gran Fondo of Marin. ... UVA and UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... return to the La Gorce Country Club in Miami Beach to host its ...
(Date:2/23/2017)... ... 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will ... to Hot,” which will begin airing on February 24, 2017. The show chronicles the ... 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... YORK , Feb. 24, 2017 ... Monteverde & Associates PC , a boutique securities firm ... New York City , announces that a class ... Massachusetts  against Inotek Pharmaceuticals Corporation ... of the Company,s securities between July 23, 2015 and December ...
(Date:2/24/2017)...  Directors from Pharma To Market Pty Ltd and Ador Consulting ... in the founding of Pharma To Market Pte Ltd, based in ... pleased to announce their expansion into Asia ... . The company are delighted to appoint Joelle Chia , ... Singapore based entity. Joelle brings with her an extensive ...
(Date:2/24/2017)...  Xynomic Pharmaceuticals, Inc., an oncology drug research ... acquired exclusive worldwide rights to develop, manufacture and ... targeting hematological and solid tumors. To ... 2 clinical trials of Abexinostat in US, EU ... been completed, demonstrating that Abexinostat is clinically active ...
Breaking Medicine Technology: